Telix Pharmaceuticals announces major partnership

TLX is a radiopharmaceutical company advancing partnerships, regulatory approvals, financial growth and development pipeline progress during 2026.

Telix Pharmaceuticals Limited (ASX: TLX)

on 13 April 2026, in  partnership with Regeneron, announced to develop and commercialize next generation radiopharmaceutical therapies. 

The contract sets a 50/50 model for distribution both costs and profits. It brings together TLX’s strength in radiopharmaceutical development and manufacturing with Regeneron’s antibody discovery platforms and oncology expertise. 

Under this deal, Telix will receive an upfront payment of US$40 million covering four initial programs. The structure also gives flexibility for each program where Telix can choose to co-fund commercialization and share profits or instead receive milestone payments and royalties. The total potential value of milestone payments can reach up to US$2.1 billion along with low double digit royalties.

FDA accepts brain cancer imaging drug

On 10 April 2026, the company shared that the U.S. FDA accepted its resubmitted New Drug Application for TLX101-Px also identified as Pixclara, a PET imaging agent for brain cancer. The agency has set a PDUFA goal date of 11 September 2026. This product is designed to improve imaging of glioma, especially in distinguishing tumor progression from treatment related changes in both adults and children. The drug has already received Orphan Drug and Fast Track designations. 
It is also widely recommended in global clinical guidelines.

If approved, it would address a main unmet need as there is presently no FDA approved targeted amino acid PET imaging agent for this condition in the United States. The company also confirmed that its financial guidance for 2026 does not contain any revenue from this product.

Future plans

Telix outlined its ongoing plans and development progress. The company is advancing key therapeutic programs including the ProstACT Phase 3 study for its prostate cancer therapy candidate TLX591-Tx, where early safety and dosing goals have been achieved without new concerns. 

It is also moving forward with regulatory steps globally. Alongside the U.S. filing for TLX101-Px, a Marketing Authorization Application has been submitted in Europe under the name Pixlumi. 

Another product TLX591-Px has already received application acceptance in China. The company remains to focus on increasing its precision medicine portfolio and strengthening its global commercial presence though progressing its late stage pipeline.

Revenue growth and business update

TLX achieved strong operational momentum for the quarter ending 31 March 2026. On 7 April 2026, it announced unaudited revenue of US$230 million for Q1 and showing an 11% increase compared to the previous quarter. 

Its precision medicine segment generated US$186 million supported by growth in its key imaging products. TLX confirmed its full year revenue guidance of US$950 million to US$970 million and expects stable performance maintained by global product sales. 

Previously on 16 March 2026, Telix had resubmitted the NDA for TLX101-Px with additional data requested by the FDA following previous feedback. The submission included expanded analysis to address earlier concerns. The product continues to target a significant unmet need in brain cancer imaging and ongoing regulatory engagement indicates progress toward potential approval.

(Source: Company Report)